After a review of evidence, the UK Health Security Agency (HSA) said today that it no longer classifies clade 1a and 1b mpox ...

Canada has an opportunity to prevent sustained Clade I mpox transmission, but only if decisive action is taken now.

Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

On August 13, 2024, the Africa Centres for Disease Control and Prevention (Africa CDC) declared the multi-country mpox ...

ATLANTA, GA - February 19, 2025 (NEWMEDIAWIRE) - The confirmation of a fourth case of Clade 1 Mpox in New York underscores the urgent need for a stronger and more diversified vaccine supply chain.

Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international ...

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...